Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
2024-04-04 00:56:46 ET Summary Novartis is now a pure player in innovative medicines. Despite a negative FX, the company reported solid 2023 financial results and increased its dividend per share. There is a strategic rationale for acquiring MorphoSys AG. NVS had raised its ou...
2024-04-02 15:38:04 ET More on Intra-Cellular Therapies Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy' I...
2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...
2024-03-28 17:59:49 ET Summary OLEMA Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with a focus on women's cancer. Their flagship drug, palazestrant, shows promising results for halting the progression of estrogen receptor-po...
2024-03-27 10:08:08 ET Summary Dimensional International Value ETF is an actively managed fund investing in companies with value characteristics outside the U.S. The portfolio is well-diversified across holdings, but quite heavy in Japanese companies and in financials. Not onl...
2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...
2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...
2024-03-12 12:09:42 ET Summary Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024. Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicyc...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
2024-03-08 14:02:46 ET More on Merck Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Merck: A Great Dividend Growth Stock, But Not At This Price Merck: A High-Conviction Investment For Long-Term Growth Gilead, Merck once we...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...